Clinical Trial Update: Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain [Phase 3]

View source ↗

Summary

Phase 3 trial of XG-102 for reducing post-cataract surgery intraocular inflammation and pain has completed, evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract
• Ocular Inflammation
• Ocular Pain

Drugs mentioned

• XG-102

Snippet

Sponsor: Xigen SA | Conditions: Inflammation, Pain | Phase 3 | Status: COMPLETED